Literature DB >> 29035118

Clinical Gene Therapy for Neurodegenerative Diseases: Past, Present, and Future.

Françoise Piguet1,2,3, Sandro Alves4, Nathalie Cartier5,6.   

Abstract

Clinical gene therapy has made important advances over the last decade. Among neurological diseases, severe genetic neurodegenerative conditions have been the focus of initial clinical applications. Gene therapy has also addressed complex neurodegenerative diseases, particularly Parkinson's disease, with encouraging results in human patients, demonstrating that specific targeting of central nervous system (CNS) cells is a relevant strategy for severe pathologies and that efficient access to the CNS with viral vectors is an achievable goal. The purpose of this review is to summarize the gene therapy clinical applications that have been conducted for neurodegenerative diseases. Limitations and hurdles to obtain and demonstrate benefit in patients, and the new developments that should allow new clinical applications with high beneficial potential are discussed.

Entities:  

Keywords:  AAV; cell-based therapies; clinical trials; delivery methods; lentivirus and other RNA viruses

Mesh:

Year:  2017        PMID: 29035118     DOI: 10.1089/hum.2017.160

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  25 in total

Review 1.  Adeno-associated virus-based Alzheimer's disease mouse models and potential new therapeutic avenues.

Authors:  Lars M Ittner; Matthias Klugmann; Yazi D Ke
Journal:  Br J Pharmacol       Date:  2019-04-23       Impact factor: 8.739

Review 2.  Transfection by cationic gemini lipids and surfactants.

Authors:  M Damen; A J J Groenen; S F M van Dongen; R J M Nolte; B J Scholte; M C Feiters
Journal:  Medchemcomm       Date:  2018-07-17       Impact factor: 3.597

3.  Noninvasive delivery of an α-synuclein gene silencing vector with magnetic resonance-guided focused ultrasound.

Authors:  Kristiana Xhima; Fadl Nabbouh; Kullervo Hynynen; Isabelle Aubert; Anurag Tandon
Journal:  Mov Disord       Date:  2018-09-28       Impact factor: 10.338

Review 4.  Development and clinical translation of ex vivo gene therapy.

Authors:  Xiaomo Wu; Xiaorong He; Fahui Liu; Xiaochang Jiang; Ping Wang; Jinyan Zhang; Ju Jiang
Journal:  Comput Struct Biotechnol J       Date:  2022-06-11       Impact factor: 6.155

Review 5.  Evolving therapies in neuronopathic LSDs: opportunities and challenges.

Authors:  Deepa S Rajan; Maria L Escolar
Journal:  Metab Brain Dis       Date:  2022-04-20       Impact factor: 3.655

Review 6.  Molecular Insights into NR4A2(Nurr1): an Emerging Target for Neuroprotective Therapy Against Neuroinflammation and Neuronal Cell Death.

Authors:  Md Jakaria; Md Ezazul Haque; Duk-Yeon Cho; Shofiul Azam; In-Su Kim; Dong-Kug Choi
Journal:  Mol Neurobiol       Date:  2019-01-25       Impact factor: 5.590

Review 7.  AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer.

Authors:  Helena Costa Verdera; Klaudia Kuranda; Federico Mingozzi
Journal:  Mol Ther       Date:  2020-01-10       Impact factor: 11.454

Review 8.  Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy.

Authors:  Nicola Specchio; Alessandro Ferretti; Marina Trivisano; Nicola Pietrafusa; Chiara Pepi; Costanza Calabrese; Susanna Livadiotti; Alessandra Simonetti; Paolo Rossi; Paolo Curatolo; Federico Vigevano
Journal:  Drugs       Date:  2021-01       Impact factor: 9.546

9.  Enforced dimerization between XBP1s and ATF6f enhances the protective effects of the UPR in models of neurodegeneration.

Authors:  René L Vidal; Denisse Sepulveda; Paulina Troncoso-Escudero; Paula Garcia-Huerta; Constanza Gonzalez; Lars Plate; Carolina Jerez; José Canovas; Claudia A Rivera; Valentina Castillo; Marisol Cisternas; Sirley Leal; Alexis Martinez; Julia Grandjean; Donzelli Sonia; Hilal A Lashuel; Alberto J M Martin; Veronica Latapiat; Soledad Matus; S Pablo Sardi; R Luke Wiseman; Claudio Hetz
Journal:  Mol Ther       Date:  2021-02-03       Impact factor: 11.454

10.  Advances in the Treatment of Neuronal Ceroid Lipofuscinosis.

Authors:  Jonathan B Rosenberg; Alvin Chen; Stephen M Kaminsky; Ronald G Crystal; Dolan Sondhi
Journal:  Expert Opin Orphan Drugs       Date:  2019-11-27       Impact factor: 0.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.